Stockscreener 앱 받기
3.01
5.24%
0.15
Savara Inc 주식(SVRA)의 최신 뉴스
Savara Reports 2024 Financial Results and Provides Updates on MOLBREEVI Progress - MSN
Savara Secures $200 Million Loan Agreement with Hercules Capital - MSN
Savara director David Ramsay acquires $416,250 in common stock By Investing.com - Investing.com Australia
Savara Insider Bought Shares Worth $416,250, According to a Recent SEC Filing - MarketScreener
Savara director David Ramsay acquires $416,250 in common stock - Investing.com India
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP - MSN
Savara IncTerminates ATM Agreement With Evercore Effective April 2, 2025SEC Filing - MarketScreener
SAVARA Earnings Preview: Recent $SVRA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval By Investing.com - Investing.com Australia
Savara Inc ends sales agreement with Evercore - Investing.com
Savara’s SWOT analysis: rare disease biotech stock eyes FDA approval - Investing.com India
Swiss National Bank Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
What is HC Wainwright’s Estimate for Savara Q1 Earnings? - Defense World
HC Wainwright Reaffirms Buy Rating for Savara (NASDAQ:SVRA) - Defense World
Savara enters loan and security agreement with Hercules Capital - MSN
Savara stock holds Buy rating, $6 target from H.C. Wainwright By Investing.com - Investing.com Australia
Savara stock holds Buy rating, $6 target from H.C. Wainwright - Investing.com India
Charles Schwab Investment Management Inc. Grows Position in Savara Inc (NASDAQ:SVRA) - Defense World
Nkarta to lay off 34% of staff; Savara’s debt financing deal - Endpoints News
Savara Inc. (SVRA) reports earnings - Quartz
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update - Joplin Globe
Breakthrough: Savara Advances First-Ever aPAP Treatment with FDA Filing, Reports $196M Cash Position - Stock Titan
JMP maintains $9 target on Savara stock, sees FDA nod By Investing.com - Investing.com South Africa
JMP maintains $9 target on Savara stock, sees FDA nod - Investing.com India
Savara secures $200M loan to support respiratory drug launch By Investing.com - Investing.com South Africa
Savara secures $200M loan to support respiratory drug launch - Investing.com
Savara Gets Up to $200 Million Loan From Hercules Capital - Marketscreener.com
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital - Bluefield Daily Telegraph
Major Financial Boost: Savara Lands $200M Debt Deal as FDA Decision Approaches - Stock Titan
Savara submits FDA application for aPAP therapy MOLBREEVI - Investing.com
Savara Completes Submission Of The Biologics License Application (BLA) To The U.S. Food And Drug Administration (FDA) For MOLBREEVI As A Treatment For Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Marketscreener.com
Breakthrough: First Treatment for Rare Lung Disease aPAP Heads to FDA Review - Stock Titan
Bank of New York Mellon Corp Purchases 17,870 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA) Stock: Investors Need To Know This - Stocks Register
Victory Capital Management Inc. Reduces Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
Savara Inc (NASDAQ:SVRA) Receives $8.83 Consensus Price Target from Analysts - Defense World
Savara Inc. to Present at Leerink Global Healthcare Conference - MSN
Breakthrough Phase 3 Results: New Treatment Reduces Lung Procedures in Rare Disease Patients - StockTitan
Savara Inc. Launches Convenient DBS Test for Diagnosing Rare Lung Disease - MSN
Oppenheimer & Co. Inc. Decreases Stock Holdings in Savara Inc (NASDAQ:SVRA) - Defense World
Rhumbline Advisers Purchases 9,041 Shares of Savara Inc (NASDAQ:SVRA) - Defense World
Savara Inc (NASDAQ: SVRA): An Enticing Stock To Watch - Stocks Register
Savara, Inc. to Host Earnings Call - ACCESS Newswire
Savara Launches Test for Autoimmune Lung Disease in US; Shares Up Pre-Bell -March 06, 2025 at 08:55 am EST - Marketscreener.com
Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
2.00%
자본화:
|
볼륨(24시간):